Predicting the Risk of Venous Thromboembolism in Newly Diagnosed Myeloma With Immunomodulatory Drugs: External Validation of the IMPEDE VTE Score

American Journal of Hematology - United States
doi 10.1002/ajh.25658
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer Into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification

TH Open
2017English

Advances in Predicting Venous Thromboembolism Risk in Children

British Journal of Haematology
Hematology
2017English

Costs of Venous Thromboembolism (Vte) Among Hospitalized Patients in China

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Validation of a Prognostic Score for Hidden Cancer in Unprovoked Venous Thromboembolism

PLoS ONE
Multidisciplinary
2018English

Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis

TH Open
2020English

Impact of Time-Varying Treatment Exposures on the Risk of Venous Thromboembolism in Multiple Myeloma

Healthcare
2016English

A Risk Score for Prediction of Recurrence in Patients With Unprovoked Venous Thromboembolism (DAMOVES)

European Journal of Internal Medicine
Internal Medicine
2016English

The Risk of Venous Thromboembolism in Patients With Heart Failure

Russian Journal of Cardiology
Cardiovascular MedicineCardiology
2020English

The Risk of Venous Thromboembolism in Patients With Rheumatoid Arthritis

Arthritis Care and Research
Rheumatology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy